Abiopharma

Perrigo Announces Quarterly Dividend

Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Nomad Foods to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

AudioEye Sets Second Quarter 2026 Earnings Call

Equity Residential and AvalonBay Announce Vivmark Residential as Name of Combined Company

Johnson & Johnsons RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

To Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Cycurion Lands Largest Contract in Company History: $54.6 Million 10-Year Award with Top-5 Global Consulting Firm

Core AI Announces Formation of Z Studio to Accelerate Expansion into Vertical AI Applications